PTCHF Stock - PureTech Health plc
Unlock GoAI Insights for PTCHF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.83M | $3.33M | $2.09M | $9.98M | $8.34M |
| Gross Profit | $1.26M | $-1,603,000 | $-136,815,000 | $-100,492,000 | $8.34M |
| Gross Margin | 26.0% | -48.1% | -6546.2% | -1007.0% | 100.0% |
| Operating Income | $-136,095,000 | $-146,199,000 | $-197,807,000 | $-150,282,000 | $-119,531,000 |
| Net Income | $53.51M | $-65,697,000 | $-50,355,000 | $-60,558,000 | $5.99M |
| Net Margin | 1108.3% | -1972.9% | -2409.3% | -606.9% | 71.8% |
| EPS | $2.00 | $-2.40 | $-1.80 | $-2.10 | $0.20 |
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Visit WebsiteEarnings History & Surprises
PTCHFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q3 2025 | Aug 28, 2025 | $-0.20 | $-0.19 | +6.9% | ✓ BEAT |
Q2 2025 | Apr 30, 2025 | $-0.28 | $0.35 | +224.8% | ✓ BEAT |
Q3 2024 | Aug 28, 2024 | $-0.30 | $-0.15 | +48.9% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $-0.33 | $-0.15 | +53.8% | ✓ BEAT |
Q2 2023 | Jun 29, 2023 | $-0.00 | $-0.09 | -2983.3% | ✗ MISS |
Q4 2022 | Dec 30, 2022 | $0.03 | $-0.08 | -337.3% | ✗ MISS |
Q2 2022 | Jun 29, 2022 | $-0.27 | $-0.09 | +66.3% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | $-0.24 | $0.05 | +120.9% | ✓ BEAT |
Q2 2021 | Jun 30, 2021 | $-0.23 | $-0.26 | -13.5% | ✗ MISS |
Q4 2020 | Dec 31, 2020 | $-0.20 | $-0.43 | -115.5% | ✗ MISS |
Q2 2020 | Jun 30, 2020 | — | $0.41 | — | — |
Q4 2019 | Dec 31, 2019 | — | $1.42 | — | — |
Q2 2019 | Jun 30, 2019 | — | $0.10 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.13 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.03 | — | — |
Q4 2017 | Dec 31, 2017 | — | $0.28 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.18 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.08 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.13 | — | — |
Latest News
Frequently Asked Questions about PTCHF
What is PTCHF's current stock price?
What is the analyst price target for PTCHF?
What sector is PureTech Health plc in?
What is PTCHF's market cap?
Does PTCHF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PTCHF for comparison